Document:

THIS
SUBSCRIPTION AGREEMENT RELATES TO AN OFFERING OF SHARES OF COMMON STOCK (THE “OFFERING”), IN AN OFFSHORE TRANSACTION
TO PERSONS WHO ARE NOT U.S. PERSONS (AS DEFINED HEREIN) PURSUANT TO REGULATION S PROMULGATED BY THE UNITED STATES SECURITIES AND
EXCHANGE COMMISSION (THE “SEC”) UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”).

 

THE
SHARES THAT ARE SUBJECT TO THIS SUBSCRIPTION AGREEMENT IN RELIANCE ON REGULATION S (THE “SUBSCRIPTION AGREEMENT” OR
THE “AGREEMENT”) HAVE NOT BEEN REGISTERED UNDER THE ACT, OR ANY U.S. STATE SECURITIES LAWS, AND, UNLESS SO REGISTERED,
NONE MAY BE OFFERED OR SOLD, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OR TO U.S. PERSONS (AS DEFINED HEREIN) EXCEPT IN ACCORDANCE
WITH THE PROVISIONS OF REGULATION S UNDER THE ACT, PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT, OR PURSUANT
TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE ACT AND IN EACH CASE
ONLY IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. IN ADDITION, HEDGING TRANSACTIONS INVOLVING THE SECURITIES MAY NOT BE
CONDUCTED UNLESS IN ACCORDANCE WITH THE ACT.

 

TECHCARE
CORP.

(a
Delaware corporation)

 

SUBSCRIPTION
AGREEMENT

DATED:
January 21, 2019 (the “Effective Date”)

 

1.
The Offering

 

1.1
On the basis of the representations and warranties and subject to the terms and conditions set forth in this Subscription Agreement,
ICB Biotechnology Investments Ltd., an Israeli corporation with offices located at 30 Habarzel St., Tel Aviv, Israel (the
“Investor”) hereby agrees to subscribe for and purchase 1,915,708 shares of common stock, par value $0.0001(the
“Initial Shares”) offered by TechCare Corp., a Delaware corporation with offices located at 1140 Avenue of
the Americas, New York, NY 10036 (the “Company”), at a purchase price per share of US$ 0.261 (the “Share
Purchase Price”), constituting 4.95% of the Company’s share capital, on a fully diluted basis (excluding outstanding
warrants), reflecting a Company’s pre money valuation of US$ 9,593,811, on a fully-diluted basis (excluding outstanding
warrants), for an aggregate consideration of US$500,000 (the “Subscription Proceeds”), all pursuant to the
terms and conditions set forth in this Subscription Agreement.

 

The
Subscription Proceeds shall be transferred to the Company in two (2) equal installments of US$250,000, each, as follows: (i) the
first installment to be transferred to the Company’s bank account, as of the Initial Closing (as defined below) (the “First
Installment”); (ii) the second installment (the “Milestone Installment”) to be transferred to the
Company’s bank account as of the Milestone Closing (as defined below) do be set immediately following the signing of a joint
venture agreement (the “JVA”) between the Company’s wholly owned subsidiary, Novomic Ltd. (the “Subsidiary”)
and China-Israel Biological Technology Co., Ltd. (“CIB”), the controlling shareholder of the Investor along
with a Patent Application Right Transfer Agreement as further detailed in the JVA; provided that certain agreed upon intellectual
property of the Subsidiary has been fully transferred, assigned and/or licensed to a Chinese joint venture to be established by
CIB and the Subsidiary under the terms of the JVA (the “Milestone Closing”).

 

1.2
In addition, on the basis of the representations and warranties and subject to the terms and conditions set forth in this Subscription
Agreement and subject to the receipt by the Company of the full amount of the Subscription Proceeds, the Investor shall be entitled,
but not obligated, until the twelve (12) month anniversary of the date hereof, to subscribe for, and purchase, 833,333 additional
Shares of the Company (the “Additional Shares” and together with the Initial Shares, the “Shares”)
at a purchase price of US$0.60, for an aggregate consideration of US$500,000 (the “Additional Subscription Proceeds”),
all pursuant to the terms and conditions set forth in this Subscription Agreement.

 

1.3
The undersigned Investor understands that this Offering by the Company is being made only to persons/institutions who are not
U.S. Persons, as defined in Rule 902 of Regulation S promulgated by the United States Securities and Exchange Commission (“SEC”)
under the Securities Act of 1933, as amended (the “Act”) and that the Company will not offer Shares nor accept
subscriptions from any person and/or entity that is not a U.S. Person as defined in Rule 902 of Regulation S.

 

1.4
On the basis of the representations and warranties of the Investor and subject to the terms and conditions set forth herein, the
Company, by its execution and delivery of the counter-signed copy of this Subscription Agreement, hereby irrevocably agrees to
accept the subscription and sell to the undersigned the Shares subscribed for herein.

 

1.5
Subject to the terms hereof, this Subscription Agreement will be effective upon receipt by the Company of the First Installment.

 

1.6
Within seven (7) days of from the receipt of the relevant installment on account of the Subscription Proceeds (the First Installment
or the Milestone Installment, as the case may be) or the Additional Subscription Proceeds by the Company, as applicable, the Company
shall deliver to the Investor book entry confirmation representing the number of Shares purchased by the Investor. The Shares
shall be registered on the books of the Company as follows: ICB Biotechnology Investments Ltd., of 30 Habarzel St., Tel Aviv,
Israel.

 

    	1

    	 

    

 

2.
Initial Closing

 

2.1
At the initial closing (the “Initial Closing”), the following transactions shall occur, which transactions
shall be deemed to take place simultaneously and no transaction shall be deemed to have been completed or any document delivered
until all such transactions have been completed and all required documents delivered:

 

2.1.1
Transactions at the Initial Closing. At the Initial Closing, against payment by the First Installment, the Company
shall deliver to the Investor the following documents, as applicable:

 

2.1.1.1
Board Resolution. True and correct copies of resolutions of the Board: (i) authorizing the issuance and sale of the
Initial Shares to the Investor against payment of the Subscription Proceeds therefor and the Additional Shares upon the payment
of the Additional Subscription Proceeds; (ii) appointing the Investor Director (as defined below) and approving his indemnification
agreement; and (iii) approving the execution, delivery and performance by the Company of this Subscription Agreement, including
all of its exhibits and schedules, and the transactions contemplated herein and therein, all in substantially the form attached
hereto as Schedule 2.1.1.12.1.1.1;

 

2.1.1.2
Compliance Certificate. A duly executed compliance certificate in the form attached hereto as Schedule 2.1.1.2;
and

 

2.1.1.3
Director Indemnification Agreement. Director indemnification agreement with the Investor Director, duly executed by
the Company, in the form attached hereto as Schedule 2.1.1.3;

 

2.1.1.4
Share Registration. The Company shall properly register the allotment of the applicable portion of the Initial Shares
to the Investor with the Company’s transfer agent.

 

2.2
Investment. The Investor shall cause the transfer to the Company of the First Instalment, by wire transfer or such other
form of payment as is mutually agreed by the Company and the Investor.

 

2.3
Board Member Appointment Letter. The Investor shall execute and deliver a written notice to the Company for the appointment
of a director on its behalf (the “Investor Director”).

 

2.4
Investor’s Board and Shareholders Approvals. The Initial Closing and Milestone Closing along with the transactions
contemplated herein shall be subject to and contingent upon the approvals of the Board of Directors and shareholders of the Investor.

 

3.
Milestone Closing

 

The
Company will issue and allot upon the Milestone Closing, the applicable portion of the Initial Shares, against the transfer by
the Investor of the Milestone Installment. The Milestone Closing shall be done following the satisfaction of all conditions set
forth herein with respect to such Milestone Closing at such date, time and place as the Company and the Investor shall mutually
agree upon to be conducted. The Milestone Closing shall be held remotely, via the exchange of documents and signatures or at such
other manner, time or place upon which the Company and the Investor shall agree.

 

3.1
Transactions at the Milestone Closing. At the Milestone Closing, the following transactions shall occur, which transactions
shall be deemed to take place simultaneously and no transaction shall be deemed to have been completed or any document delivered
until all such transactions have been completed and all required documents delivered:

 

3.1.1
Payment. The Investor shall cause the transfer to the Company of the Milestone Installment, by wire transfer in accordance
with written instructions to be provided by the Company;

 

3.1.2
Shares Issuance. The Company shall issue and allot to the Investor the applicable portion of the Initial Shares. The Company
shall properly register the allotment and transfer of the applicable portion of the Initial Shares to the Investor with the Company’s
transfer agent;

 

3.1.3
Joint Venture Agreement. CIB and the Subsidiary shall execute the JVA to be attached hereto as Schedule 3.1.3;
and

 

3.1.4
China IP Agreement. CIB and the Subsidiary shall enter into the China IP Agreement, regarding the Subsidiary’s technology,
in the form to be attached hereto as Schedule 3.1.4.

 

4.
Payment of Subscription Proceeds and Additional Subscription Proceeds

 

The
Investor understands that the Subscription Proceeds and Additional Subscription Proceeds, as applicable, are payable to the Company
by electronic wire transfer pursuant to the Company’s wiring instructions to be provided thereto.

 

5.
Documents/Deliveries Required from the Investor

 

5.1
The Investor understands and agrees that as a condition to the Company’s acceptance of this subscription, the undersigned
will complete, sign and return to the Company an executed copy of this Subscription Agreement together with any and all attachments
hereto.

 

5.2
The Investor will complete, sign and return to the Company as soon as possible, on request by the Company, any other documents,
questionnaires, notices and undertakings as may be reasonably required by regulatory authorities and applicable law.

 

    	2

    	 

    

 

5.3
The Investor will pay/deliver the Subscription Proceeds and the Additional Subscription Proceeds, as applicable, to the Company,
as provided in Section 4 above, subject to the Company’s execution and acceptance of this Subscription Agreement.

 

6.
Acknowledgements of Investor

 

6.1
The Investor acknowledges and agrees that without derogating from the Company’s representations and warranties set forth
herein:

 

(i)
the Shares being offered have not been registered under the Act, or under any state securities or “blue sky” laws
of any state of the United States, and, unless so registered, the Shares may neither be offered nor sold in the United States
or, directly or indirectly, to U.S. Persons, as that term is defined in Rule 902 of Regulation S under the Act, except in accordance
with the provisions of Regulation S, pursuant to an effective registration statement under the Act, or pursuant to an exemption
from, or in a transaction not subject to, the registration requirements of the Act;

 

(ii)
the Investor acknowledges that the Company has not undertaken, and will have no obligation, to register the under the Act;

 

(iii)
the decision to execute this Subscription Agreement is based upon the representations and warranties made by the Company under
this Subscription Agreement, including the review of information (the receipt of which is hereby acknowledged) which has been
filed by the Company with the SEC under the Securities Exchange Act of 1934 (collectively, the “Exchange act Reports”);

 

(iv)
no securities commission or similar regulatory authority has reviewed or passed on the merits of an investment in the Shares;

 

(v)
there is no government or other insurance covering any investment in the Shares;

 

(vi)
there are risks associated with an investment in the Shares, as more fully described in certain information forming part of the
Exchange Act Reports;

 

(vii)
the Investor has had a reasonable opportunity to ask questions of and receive answers from the Company in connection with the
Offering and to obtain additional information, to the extent possessed or obtainable without unreasonable effort or expense, necessary
to verify the accuracy of the information about the Company;

 

(viii)
the books and records of the Company were available upon reasonable notice for inspection, subject to certain confidentiality
restrictions, by the Investor during reasonable business hours at its principal place of business, and all documents, records
and books in connection with the distribution of the Shares hereunder have been made available for inspection by the Investor,
the Investor’s attorney and/or advisor(s), if any;

 

(ix)
there is no guarantee that the Shares will be listed on any stock exchange or automated dealer quotation system and no representation
has been made to the Investor that the Shares will be listed on any stock exchange or automated dealer quotation system;

 

(x)
the Shares are assignable only with the prior written consent of the Company, which consent will not be unreasonably denied, provided
that any such transfer is made in accordance with the provisions of Regulation S, pursuant to an effective registration statement
under the Act or pursuant to an available exemption from the registration requirements of the Act; and

 

(xi)
this Subscription Agreement is not enforceable by the Investor unless it has been accepted by the Company.

 

7.
Representations, Warranties and Covenants of the Investor

 

7.1
The Investor hereby represents and warrants to and covenants with the Company (which representations, warranties and covenants
shall be true and correct as of the date hereof and as of the subscription date of the Additional Shares, and will survive the
execution and delivery of this Subscription Agreement) that:

 

(i)
the Investor has the legal capacity and competence to enter into and execute this Subscription Agreement and to take all actions
required pursuant hereto and, if the Investor is a corporation, it is duly incorporated and validly subsisting under the laws
of its jurisdiction of incorporation and all necessary approvals by its directors, shareholders and others have been obtained
to authorize execution and performance of this Subscription Agreement on behalf of the Investor;

 

(ii)
entering into of this Subscription Agreement and the transactions contemplated hereby do not result in the violation of any of
the terms and provisions of any law applicable to, or the corporate documents of, the Investor or of any agreement, written or
oral, to which the Investor may be a party or by which the Investor is or may be bound;

 

(iii)
the Investor has duly executed and delivered this Subscription Agreement and it constitutes a valid and binding agreement of the
Investor enforceable against the Investor subject to laws of general application relating to bankruptcy, insolvency and the relief
of debtors and rules of law governing specific performance, injunctive relief or other equitable remedies;

 

(iv)
the Investor is not a U.S. Person;

 

    	3

    	 

    

 

(v)
the Investor is not acquiring the Shares for the account or benefit of, directly or indirectly, any U.S. Person;

 

(vi)
the Investor is resident of the jurisdiction set out under the heading “Name and Address of Investor” on the
signature page of this Subscription Agreement;

 

(vii)
the Investor is and will be outside the United States when receiving and executing this Subscription Agreement and is acquiring
the Shares as principal for the Investor’s own account (except for the circumstances outlined in paragraph 7.1), for investment
purposes only, and not with a view to, or for, resale, distribution or fractionalization thereof, in whole or in part, and no
other person has a direct or indirect beneficial interest in the Shares;

 

(viii)
the Investor is acquiring the Shares for investment only and not with a view to resale or distribution and, in particular, it
has no intention to distribute either directly or indirectly any of the Shares in the United States or to U.S. Persons;

 

(ix)
the Investor is not an underwriter of, or dealer in, the Shares of the Company, nor is the Investor participating, pursuant to
a contractual agreement or otherwise, in the distribution of the Shares;

 

(x)
the Investor:

 

(a)
is able to fend for itself in connection with the Offering; and

 

(b)
has such knowledge and experience in business matters as to be capable of evaluating the merits and risks of its prospective investment
in the Company’s Shares offered hereby; and

 

(c)
has the ability to bear the economic risks of its prospective investment and can afford the complete loss of such investment;

 

(xi)
if the Investor is acquiring the Shares as a fiduciary or agent for one or more investor accounts, the Investor has sole investment
discretion with respect to each such account and it has full power to make the foregoing acknowledgements, representations and
agreements on behalf of such account, and the investor accounts, if any, for which the Investor acts as a fiduciary or agent satisfy
the definition of an “Accredited Investor”, as the term is defined in Rule 501 of Regulation D under the Act;

 

(xii)
the Investor acknowledges that the Investor has not acquired the Shares as a result of, and will not itself engage in, any “directed
selling efforts” (as defined in Regulation S under the Act) in the United States in respect of any of the Shares which would
include any activities undertaken for the purpose of, or that could reasonably be expected to have the effect of, conditioning
the market in the United States for the resale of any of the Shares, provided, however, that the Investor may sell or otherwise
dispose of any of the Shares pursuant to an effective registration statement under the Act and any applicable state securities
laws or under an exemption from such registration requirements and as otherwise provided herein;

 

(xiv)
the Investor acknowledges that:

 

(a)
he has not received nor is he aware of any advertisement of any of the Shares;

 

(b)
no person has made to the Investor any written or oral representations that any person will resell or repurchase any of the Shares;
and

 

(c)
no person will refund the purchase price of any of the Shares.

 

8.
Conditions Precedent.

 

The
undertaking of the Investor shall be subject to and contingent upon the following:

 

8.1
Prior to the Effective Date, the Company shall have secured all permits, consents and authorizations that shall be necessary or
required lawfully to consummate this Subscription Agreement and to issue Shares and the Additional Shares, as applicable, in accordance
with the terms of this Subscription Agreement. The Company has all requisite corporate power to own and operate its property and
assets, to perform all its obligations under all agreements and instruments to which it is a party or by which it is bound, and
to carry on the business of the Company as presently conducted and as proposed to be conducted. The Company is in compliance with
all applicable laws, including all laws pertaining to it as a public company. All issued and outstanding shares of the Company
have been duly authorized, and are validly issued and outstanding and fully paid and non-assessable. The Shares and the Additional
Shares, when issued in accordance with this Subscription Agreement, will be duly authorized, validly issued, fully paid, non-assessable,
and free of any preemptive rights, and will have the rights, preferences, privileges, and restrictions set forth in the Certificate
of Incorporation of the Company, and will be issued free and clear of any liens, claims, encumbrances or third party rights of
any kind and duly registered in the name of the Investor in the Company’s register of members.

 

8.2
The Company has duly executed and delivered this Subscription Agreement and it constitutes a valid and binding agreement of the
Company enforceable against the Company.

 

8.3
The acquisition of and subscription for the Shares and the Additional Shares by the Investor as contemplated in this Subscription
Agreement complies with or is exempt from the applicable securities legislation of the jurisdiction of residence of the Investor.

 

    	4

    	 

    

 

8.4
The following representations by the Company shall be true and current as of the date hereof and as of the date of the Initial
Closing and the Milestone Closing, as applicable:

 

8.4.1
The Company (directly or through the Subsidiary) owns and has developed, or has the right to use, free and clear of all liens,
charges, claims and restrictions, all patents, trademarks, service marks, trade names, copyrights, licenses and rights, and all
trade secrets, including know-how, inventions, designs, processes, works of authorship, computer programs and technical data and
information used and sufficient for use in the conduct of its business as presently conducted (collectively herein “Intellectual
Property”), without, to the best knowledge of the Company, infringing upon the right or claimed right of any other person
or entity under or with respect to the foregoing, including without limitation, the past and present employees and employers of
the past and present employees and consultants of the Company. The Company and the Subsidiary have not received or is aware of
any communications alleging that the Company or the Subsidiary or an employee or a consultant of the Company or the Subsidiary
has violated, or by conducting the Company’s or the Subsidiary’s business, would violate, patents, trademarks, service
marks, trade names, copyrights or trade secrets or other proprietary rights of other persons or entities, nor is the Company nor
the Subsidiary aware of any similar violation of the Company’s Intellectual Property by others.

 

8.4.2
Schedule 8.4.2 identifies each: (i) registered patent, trademark, copyright, domain name or registration which has
been issued to the Company with respect to any of the Company’s Intellectual Property; (ii) pending patent, trademark or
copyright application or application for registration which the Company or the Subsidiary has made with respect to any of the
Company’s Intellectual Property; (iii) each trade name or unregistered trademark used by the Company or the Subsidiary;
and (iv) license, agreement, or other permission pursuant to which the Company or the Subsidiary has received from or granted
to any third party with respect to any of the Company’s or the Subsidiary’s Intellectual Property and the material
terms thereof (hereinafter collectively the “Company IP”) other than licenses for off the shelf software. The
Company has delivered to the Investor correct and complete copies of all such patents copyrights and trademarks registrations,
patent applications, licenses, agreements, and permissions (as amended to date) and has made available to the Investor correct
and complete copies of all other written documentation evidencing ownership and prosecution (if applicable) of each such item.

 

8.4.3
Except as set forth in Schedule 8.4.2, there are no outstanding options, licenses, or agreements of any kind relating
to the foregoing, nor is the Company or the Subsidiary bound by or a party to any options, licenses or agreements of any kind
with respect to the patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses, information, proprietary
rights and processes of any other person or entity. Except as set forth in Schedule 8.4.3 and for off the shelf
licenses the Company or the Subsidiary is not obligated or under any liability whatsoever to make any payments by way of royalties,
fees or otherwise to any owner or licensee of, or other claimant to, any patent, trademark, service mark, trade name, copyright
or other intangible asset, with respect to the use thereof or in connection with the conduct of its business as presently conducted.

 

8.4.4
Any and all Intellectual Property of any kind which has been developed or is currently being developed, by any employee or consultant
of the Company or the Subsidiary (including the Company’s founders) in the course of their employment by or services provision
to the Company or the Subsidiary, is and shall be the property solely of the Company or the Subsidiary. The Company and the Subsidiary
has taken all reasonably required security measures to protect the secrecy, confidentiality and value of all the Intellectual
Property, which measures are reasonable and customary in the industry in which the Company operates. All of the Company’s
and the Subsidiary’s employees and consultants, past and present, who, either alone or in concert with others developed,
invented or discovered the Company IP or had access to confidential information of the Company or the Subsidiary have entered
into written agreements with the Company or the Subsidiary assigning to the Company or the Subsidiary all rights in the Company
IP. True and correct copies of all such agreements have been provided to the Investor prior to the Initial Closing.

 

8.4.5
The Company and the Subsidiary have not collected, processed, transferred or stored any personally identifiable information/personal
data of any third parties except in compliance with applicable law. The Company and the Subsidiary has complied with applicable
legal requirements and its internal privacy policies relating to the use, processing, collection, storage, disclosure and transfer
of any personally identifiable information/personal data collected by the Company or the Subsidiary or by third parties having
authorized access to the records of the Company or the Subsidiary. Any collection of non-personally identifiable information/personal
data of any third parties was done in compliance with applicable law.

 

9.
COMPANY’S COVENANTS

 

Without
limiting any other covenants and provisions hereof, the Company covenants and agrees that it will observe each of the following
covenants. Any of the following covenants may be waived by the written consent of the Investor.

 

9.1
Director & Officer Liability Insurance. The Company will maintain at all times, its current (or improved if decided
by the Board) director and officer liability insurance.

 

9.2
Non-Disclosure and Proprietary. Each officer, employee and consultant of the Company and the Subsidiary has signed or will
sign a non-disclosure and proprietary agreement protecting the Company’s and the Subsidiary’s rights as deemed appropriate
by the Company’s legal counsel.

 

9.3
Budget. The Board shall approve the Company’s Budget and business plan for the fiscal year of 2019.

 

    	5

    	 

    

 

10.
9.4 Investor Director. Immediately following the Initial Closing and for as long as the Investor holds more than 2%
of the Company’s capital stock on a fully-diluted basis, the Investor shall be entitled to nominate one (1) member to the
Board and any committee thereof. Acknowledgement and Waiver

 

The
Investor has acknowledged that the decision to subscribe for and purchase the Shares was made on the basis of publicly available
information contained in the Exchange Act Reports and due diligence materials provided by the Company to the Investor and its
counsel.

 

11.
Restrictive Legend on Subject Securities

 

11.1
The Investor hereby acknowledges that upon the issuance thereof, and until such time as the same is no longer required under the
applicable securities laws and regulations, certificates or book entry forms evidencing the Shares will bear a legend in substantially
the following form:

 

THE
SECURITIES REPRESENTED BY THE SHARES HAVE BEEN OFFERED IN AN OFFSHORE TRANSACTION TO A PERSON WHO IS NOT A U.S. PERSON (AS DEFINED
HEREIN) PURSUANT TO REGULATION S UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”).

 

NONE
OF THE SHARES HAVE BEEN REGISTERED UNDER THE ACT, OR ANY U.S. STATE SECURITIES LAWS, AND, UNLESS SO REGISTERED, MAY NOT BE OFFERED
OR SOLD, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OR TO U.S. PERSONS EXCEPT IN ACCORDANCE WITH THE PROVISIONS OF REGULATION
S UNDER THE ACT, PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT, OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR
IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE ACT AND IN EACH CASE ONLY IN ACCORDANCE WITH APPLICABLE
STATE SECURITIES LAWS. IN ADDITION, HEDGING TRANSACTIONS INVOLVING THE SHARES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE
ACT. “UNITED STATES” AND “U.S. PERSON” ARE AS DEFINED BY REGULATION S UNDER THE ACT.

 

11.2
The Investor hereby acknowledges and agrees to the Company making a notation on its records in order to implement the restrictions
on transfer set forth and described in this Subscription Agreement.

 

12.
Costs

 

Each
party hereto shall pay its own expenses in connection with the registration and preparation of this Agreement and the consummation
of the transactions contemplated hereby, provided however, that subject to the consummation of the Initial Closing, the Company
shall pay the Investor at the Initial Closing from the proceeds of the First Installment all legal and administrative costs of
the Investor, including reasonable fees and expenses of the Investor, such amount not to exceed in the aggregate US$15,000 plus
VAT.

 

13.
Governing Law

 

This
Subscription Agreement is governed by the laws of the State of New York. The Investor, in his personal or corporate capacity and,
if applicable, on behalf of each beneficial purchaser for whom it is acting, irrevocably agrees to the jurisdiction of the courts
of the State of New York.

 

14.
Survival

 

This
Subscription Agreement, including without limitation the representations, warranties and covenants contained herein, will survive
and continue in full force and effect and be binding upon the parties hereto notwithstanding the completion of the purchase of
the Shares by the Investor pursuant hereto.

 

15.
Assignment

 

This
Subscription Agreement is transferable or assignable only with the prior written consent of the Company, which consent will not
be unreasonably denied, provided that the Investor may assign its rights and obligations hereunder to any of its affiliates.

 

16.
Severability

 

The
invalidity or unenforceability of any particular provision of this Subscription Agreement will not affect or limit the validity
or enforceability of the remaining provisions of this Subscription Agreement.

 

17.
Entire Agreement

 

Except
as expressly provided in this Subscription Agreement and in the agreements, instruments and other documents contemplated or provided
for herein, this Subscription Agreement contains the entire agreement between the parties with respect to the sale of the Shares
and there are no other terms, conditions, representations or warranties, whether expressed, implied, oral or written, by statute
or common law, by the Company or by anyone else.

 

18.
Notices

 

All
notices here under will be in writing and will be deemed to have been duly given if mailed or transmitted by any standard form
of telecommunication. Notices to the Investor will be directed to the address on the Investor’s signature page and notices
to the Company will be directed to it at the address first set forth above unless another address will be provided to the Investor
by the Company in writing.

 

    	6

    	 

    

 

19.
Counterparts and Electronic Means

 

This
Subscription Agreement may be executed in any number of counterparts, each of which, when so executed and delivered, will constitute
an original and all of which together will constitute one instrument. Delivery of an executed copy of this Subscription Agreement
by electronic facsimile transmission or other means of electronic communication capable of producing a printed copy will be deemed
to be execution and delivery of this Subscription Agreement as of the date hereinafter set forth.

 

IN
WITNESS WHEREOF the Investor has duly executed this Subscription Agreement as of the date of acceptance by the Company.

 

	ICB
    Biotechnology Investments Ltd.	 
	(Name
    of Investor)	 
	 	 
	 	 
	(Signature
    of Investor)	 
	 	 
	 	 
	(Address
    of Investor)	 

 

ACCEPTANCE

 

The
above-mentioned Subscription Agreement in respect of the Shares is hereby accepted by TechCare Corp.

 

DATED
this ___day of January, 2019.

 

TechCare
Corp.

 

	/s/:	 	 
	Name:	Zvi
    Yemini Title: Chairman	 
	Title:	Chairman	 

 

    	7FORM
OF INDEMNIFICATION AGREEMENT

 

This
Agreement is made as of the ___ day of _____, 20__, by and between TechCare Corp., a Delaware corporation (the
“Corporation”), and _____ (“Indemnitee”), a director and/or officer of the Corporation.

 

WHEREAS,
it is essential to the Corporation to retain and attract as directors and officers the most capable persons available;

 

WHEREAS,
it is the express policy of the Corporation to indemnify its directors and officers so as to provide them with the maximum possible
protection permitted by law; and

 

WHEREAS,
Indemnitee is a director or officer of the Corporation;

 

WHEREAS,
both the Corporation and Indemnitee recognize the increased risk of litigation and other claims being asserted against directors
and officers of corporations;

 

WHEREAS,
in recognition of Indemnitee’s need for substantial protection against personal liability and in order to induce Indemnitee
to serve or continue to serve the Corporation, the Corporation wishes to provide Indemnitee with the benefits contemplated by
this Agreement to the fullest extent permitted by law;

 

NOW
THEREFORE, in consideration of the above premises and intending to be legally bound hereby, the parties agree as follows:

 

1.
Agreement to Serve. Indemnitee agrees to serve or continue to serve as director and/or officer of the Corporation for so
long as he or she is duly elected or appointed or until such time as he or she tenders his or her resignation in writing.

 

2.
Definitions. As used in this Agreement:

 

		(a)	“Change
                                         in Control” shall be deemed to have occurred if (i) any “person” (as
                                         such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934,
                                         as amended (the “Exchange Act”)), other than a trustee or other fiduciary
                                         holding securities under an employee benefit plan of the Corporation or a corporation
                                         owned directly or indirectly by the shareholders of the Corporation in substantially
                                         the same proportions as their ownership of stock of the Corporation, becomes the “Beneficial
                                         Owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly,
                                         of securities of the Corporation representing 20% or more of the total voting power represented
                                         by the Corporation’s then outstanding Voting Securities, or (ii) during any period
                                         of two consecutive years, individuals who at the beginning of such period constitute
                                         the Board and any new director whose election by the Board or nomination for election
                                         by the Corporation’s shareholders was approved by a vote of at least two-thirds
                                         (2/3) of the directors then still in office who either were directors at the beginning
                                         of the period or whose election or nomination for election was previously so approved,
                                         cease for any reason to constitute a majority thereof, or (iii) the shareholders of the
                                         Corporation approve a merger or consolidation of the Corporation with any other corporation,
                                         other than a merger or consolidation that would result in the Voting Securities of the
                                         Corporation outstanding immediately prior thereto continuing to represent (either by
                                         remaining outstanding or by being converted into Voting Securities of the surviving entity)
                                         at least 80% of the total voting power represented by the Voting Securities of the Corporation
                                         or such surviving entity outstanding immediately after such merger or consolidation,
                                         or the shareholders of the Corporation approve a plan of complete liquidation of the
                                         Corporation or an agreement for the sale or disposition by the Corporation (in one transaction
                                         or a series of transactions) of all or substantially all of the Corporation’s assets.

 

    	 	 	 

     

    

 

		(b)	The
                                         term “Corporate Status” shall mean the status of a person who is or was a
                                         director and/or officer of the Corporation, or is or was serving, or has agreed to serve,
                                         at the request of the Corporation, as a director, officer, partner, trustee, employee
                                         or agent of another corporation, partnership, joint venture, trust or other enterprise.
	 	 	 
		(c)	The
                                         term “Expenses” shall include, without limitation, attorneys’ fees,
                                         retainers, court costs, transcript costs, fees of experts, reasonable travel expenses
                                         approved in advance by the Corporation, duplicating costs, printing and binding costs,
                                         telephone charges, postage, delivery service fees and other disbursements or expenses
                                         of the types customarily incurred in connection with investigations, judicial or administrative
                                         proceedings or appeals, but shall not include the amount of judgments, fines or penalties
                                         against Indemnitee or amounts paid in settlement in connection with such matters.
	 	 	 
		(d)	The
                                         term “Independent Counsel” shall mean an attorney admitted to practice in
                                         the State of Delaware, selected by Indemnitee and approved and appointed by a majority
                                         vote of a quorum consisting of Disinterested Directors, as defined in Paragraph 9.
	 	 	 
		(e)	References
                                         to “other enterprise” shall include employee benefit plans; references to
                                         “fines” shall include any excise tax assessed with respect to any employee
                                         benefit plan; references to “serving at the request of the Corporation” shall
                                         include any service as a director, officer, employee or agent of the Corporation which
                                         imposes duties on, or involves services by, such director, officer, employee or agent
                                         with respect to an employee benefit plan, its participants or beneficiaries; and a person
                                         who acted in good faith and in a manner he reasonably believed to be in the interests
                                         of the participants and beneficiaries of an employee benefit plan shall be deemed to
                                         have acted in a manner “not opposed to the best interests of the Corporation”
                                         as referred to in this Agreement.
	 	 	 
		(f)	The
                                         term “Proceeding” shall include any threatened, pending or completed action,
                                         suit or proceeding, whether brought by or in the right of the Corporation or otherwise
                                         and whether of a civil, criminal, administrative or investigative nature, and any appeal
                                         therefrom.
	 	 	 
		(g)	The
                                         term “Voting Securities” shall mean securities of the Corporation that vote
                                         generally in the election of directors.

 

3.
Indemnification in Third-Party Proceedings. The Corporation shall indemnify Indemnitee in accordance with the provisions
of this Paragraph 3 if Indemnitee was or is a party to or threatened to be made a party to or otherwise involved in any Proceeding
(other than a Proceeding by or in the right of the Corporation to procure a judgment in its favor) by reason of Indemnitee’s
Corporate Status or by reason of any action alleged to have been taken or omitted in connection therewith, against all Expenses,
judgments, fines, penalties and amounts paid in settlement actually and reasonably incurred by Indemnitee or on Indemnitee’s
behalf in connection with such Proceeding, if Indemnitee acted in good faith and in a manner which Indemnitee reasonably believed
to be in, or not opposed to, the best interests of the Corporation and, with respect to any criminal Proceeding, had no reasonable
cause to believe that Indemnitee’s conduct was unlawful. The termination of any Proceeding by judgment, order, settlement,
conviction or upon a plea of nolo contendere, or its equivalent, shall not, of itself, create a presumption that Indemnitee did
not act in good faith and in a manner which Indemnitee reasonably believed to be in, or not opposed to, the best interests of
the Corporation and, with respect to any criminal Proceeding, had reasonable cause to believe that Indemnitee’s conduct
was unlawful.

 

    	 	 	 

     

    

 

4.
Indemnification in Proceedings by or in the Right of the Corporation. The Corporation shall indemnify Indemnitee in accordance
with the provisions of this Paragraph 4 if Indemnitee is a party to or threatened to be made a party to or otherwise involved
in any Proceeding by or in the right of the Corporation to procure a judgment in its favor by reason of Indemnitee’s Corporate
Status or by reason of any action alleged to have been taken or omitted in connection therewith, against all Expenses and, to
the extent permitted by law, judgment, fines, penalties and amounts paid in settlement actually and reasonably incurred by Indemnitee
or on Indemnitee’s behalf in connection with such Proceeding, if Indemnitee acted in good faith and in a manner which Indemnitee
reasonably believed to be in, or not opposed to, the best interests or the Corporation, except that no indemnification shall be
made under this Paragraph 4 in respect to any claim, issue or matter as to which Indemnitee shall have been adjudged to be liable
to the Corporation, unless and only to the extent that a court of proper jurisdiction shall determine upon application that, despite
the adjudication of such liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled
to indemnity for such Expenses as such court shall deem proper.

 

5.
Exceptions to Right of Indemnification. Notwithstanding anything to the contrary in this Agreement, except as set forth
in Paragraph 10, the Corporation shall not indemnify Indemnitee in connection with a Proceeding (or part thereof) initiated by
Indemnitee unless (i) the initiation thereof was approved by the Board of Directors of the Corporation; or (ii) the Proceeding
is instituted after a Change in Control. Notwithstanding anything to the contrary in this Agreement, the Corporation shall not
indemnify Indemnitee to the extent Indemnitee is reimbursed from the proceeds of insurance, and in the event the Corporation makes
any indemnification payments to Indemnitee and Indemnitee is subsequently reimbursed from the proceeds of insurance, Indemnitee
shall promptly refund such indemnification payments to the Corporation to the extent of such insurance reimbursement.

 

6.
Indemnification of Expenses. Notwithstanding any other provision of this Agreement, to the extent that Indemnitee has been
successful, on the merits or otherwise, in defense of any Proceeding or in defense of any claim, issue or matter therein, Indemnitee
shall be indemnified against all Expenses incurred by Indemnitee or on Indemnitee’s behalf in connection therewith. Without
limiting the foregoing, if any Proceeding or any claim, issue or matter therein is disposed of, on the merits or otherwise (including
a disposition without prejudice), without (i) the disposition being adverse to the Indemnitee, (ii) an adjudication that the Indemnitee
was liable to the Corporation, (iii) a plea of guilty or nolo contendere by the Indemnitee, (iv) an adjudication that the Indemnitee
did not act in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Corporation,
and (v) with respect to any criminal proceeding, an adjudication that the Indemnitee had reasonable cause to believe his conduct
was unlawful, Indemnitee shall be considered for the purposes hereof to have been wholly successful with respect thereto. In addition,
notwithstanding any other provision contained in this Agreement, to the extent that Indemnitee is, by reason of his/her Corporate
Status, a witness to any Proceeding to which Indemnitee is not a party, Indemnitee shall be indemnified and held harmless from
all Expenses actually and reasonable incurred by Indemnitee in connection therewith.

 

    	 	 	 

     

    

 

7.
Notification and Defense of Claim. As a condition precedent to Indemnitee’s right to be indemnified, Indemnitee agrees
to notify the Corporation in writing as soon as reasonably practicable of any Proceeding for which indemnity will or could be
sought by Indemnitee and provide the Corporation with a copy of any summons, citation, subpoena, complaint, indictment, information
or other document relating to such Proceeding with which Indemnitee is served; provided, however, that the failure to give such
notice shall not relieve the Corporation of its obligations to Indemnitee under this Agreement, except to the extent, if any,
that the Corporation is actually prejudiced by the failure to give such notice. With respect to any Proceeding of which the Corporation
is so notified, the Corporation will be entitled to participate therein at its own expense and/or to assume the defense thereof
at its own expense, with legal counsel reasonably acceptable to Indemnitee. After notice from the Corporation to Indemnitee of
its election so to assume such defense, the Corporation shall not be liable to the Indemnitee for any legal or other expenses
subsequently incurred by the Indemnitee in connection with such Proceeding, other than as provided below in this Paragraph 7.
Indemnitee shall have the right to employ Indemnitee’s own counsel in connection with such Proceeding, but the fees and
expenses of such counsel incurred after notice from the Corporation of its assumption of the defense thereof shall be at the expense
of Indemnitee unless (i) the employment of counsel by Indemnitee has been authorized by the Board of Directors of the Corporation,
(ii) counsel to Indemnitee shall have reasonably concluded that there may be a conflict of interest or position on any significant
issue between the Corporation and Indemnitee in the conduct of the defense of such Proceeding, (iii) after a Change in Control,
Indemnitee’s employment of its own counsel has been approved by the Independent Counsel, or (iv) the Corporation shall not
in fact have employed counsel to assume the defense of such Proceeding, in each of which cases the fees and expenses of counsel
for Indemnitee shall be at the expense of the Corporation, except as otherwise expressly provided by this Agreement. The Corporation
shall not be entitled, without the consent of Indemnitee, to assume the defense of any claim brought by or in the right of the
Corporation or as to which counsel for Indemnitee shall have reasonably made the conclusion provided for in clause (ii) above.
The Corporation shall not be required to indemnify Indemnitee under this Agreement for any amounts paid in settlement of any Proceeding
effected without its written consent, provided, however, that if a Change in Control has occurred, the Corporation shall
be liable for indemnification of Indemnitee for amounts paid in settlement if the Independent Counsel has approved the settlement.
The Corporation shall not settle any Proceeding in any manner which would impose any penalty or limitation on Indemnitee without
Indemnitee’s written consent. Neither the Corporation nor the Indemnitee will unreasonably withhold its consent to any proposed
settlement.

 

8.
Advancement of Expenses. Any Expenses incurred by Indemnitee in connection with any such Proceeding to which Indemnitee
was or is a witness or a party or is threatened to be a party by reason of his Corporate Status or by reason of any action alleged
to have been taken or omitted in connection therewith shall be paid by the Corporation in advance of the final disposition of
such matter; provided, however, that the payment of such Expenses incurred by the Indemnitee in advance of the final disposition
of such matter shall be made only upon receipt of an undertaking by or on behalf of the Indemnitee to repay all amounts so advanced
in the event that it shall ultimately be determined that the Indemnitee is not entitled to be indemnified by the Corporation as
authorized in this Agreement; and further provided that no such advancement of Expenses shall be made if it is determined that
(i) Indemnitee did not act in good faith and in a manner Indemnitee reasonably believes to be in, or not opposed to, the best
interests of the Corporation, or (ii) with respect to any criminal action or proceeding, the Indemnitee had reasonable cause to
believe Indemnitee’s conduct was unlawful. Such undertaking shall be accepted without reference to the financial ability
of Indemnitee to make such repayment. If, pursuant to the terms of this Agreement, Indemnitee is not entitled to be indemnified
with respect to such Proceeding, then such Expenses shall be paid within 60 days after the receipt by Indemnitee of the written
request by the Corporation for the Indemnitee to make payments to the Corporation.

 

    	 	 	 

     

    

 

9.
Procedure for Indemnification. In order to obtain indemnification pursuant to Paragraphs 3, 4 or 6 of this Agreement, Indemnitee
shall submit to the Corporation a written request, including in such request such documentation and information as is reasonably
available to Indemnitee and is reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification
or advancement of Expenses. Any such indemnification or advancement of Expenses shall be made promptly, and in any event within
60 days after receipt by the Corporation of the written request of the Indemnitee, unless with respect to requests under Paragraphs
3 or 4 the Corporation determines within such 60-day period that such Indemnitee did not meet the applicable standard of conduct
set forth in Paragraphs 3 or 4, as the case may be. Such determination, and any determination pursuant to Paragraph 8 that advanced
Expenses must be repaid to the Corporation, shall be made in each instance (a) by a majority vote of the directors of the Corporation
consisting of persons who are not at that time parties to the Proceeding (“Disinterested Directors”), whether or not
a quorum, (b) by a committee of Disinterested Directors designated by majority vote of Disinterested Directors, whether or not
a quorum, (c) if there are no Disinterested Directors, or if Disinterested Directors so direct, by independent legal counsel (who
may, to the extent permitted by applicable law, be regular legal counsel to the Corporation) in a written opinion or (d) by the
stockholders.

 

10.
Remedies. The right to indemnification and immediate advancement of Expenses as provided by this Agreement shall be enforceable
by the Indemnitee in any court of competent jurisdiction. Unless otherwise required by law, the burden of proving that indemnification
is not appropriate shall be on the Corporation. Neither the failure of the Corporation to have made a determination prior to the
commencement of such action that indemnification is proper in the circumstances because Indemnitee has met the applicable standard
of conduct, nor an actual determination by the Corporation pursuant to Paragraph 9 that Indemnitee has not met such applicable
standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard
of conduct. Indemnitee’s expenses (of the type described in the definition of “Expenses” in Paragraph 2 (c))
reasonably incurred in connection with successfully establishing Indemnitee’s right to indemnification, in whole or in part,
in any such Proceeding also shall be indemnified by the Corporation.

 

11.
Partial Indemnification. If Indemnitee is entitled under any provision of this Agreement to indemnification by the Corporation
for some or a portion of the Expenses, judgments, fines penalties or amounts paid in settlement actually and reasonably incurred
by Indemnitee or on Indemnitee’s behalf in connection with any Proceeding but not, however, for the total amount thereof,
the Corporation shall nevertheless indemnify Indemnitee for the portion of such Expenses, judgments, fines, penalties or amounts
paid in settlement to which Indemnitee is entitled.

 

    	 	 	 

     

    

 

12.
Establishment of Trust. In the event of a Change in Control, the Corporation shall, upon written request by Indemnitee,
create a trust for the benefit of Indemnitee and from time to time upon written request of Indemnitee shall fund the trust in
an amount sufficient to satisfy any and all claims hereunder, including Expenses, reasonably anticipated at the time of each such
request to be incurred in connection with investigating, preparing for, participating in, or defending any Proceeding as described
in Paragraphs 3 and 4. The amount or amounts to be deposited in the trust pursuant to the foregoing funding obligation shall be
determined by the Independent Counsel. The terms of the trust shall provide that upon a Change in Control, (i) the trust shall
not be revoked or the principal thereof invaded, without the written consent of Indemnitee, (ii) the trustee shall advance, within
ten (10) business days of a request by Indemnitee, any and all Expenses to Indemnitee, (iii) the trust shall continue to be funded
by the Corporation in accordance with the funding obligation set forth above, (iv) the trustee shall promptly pay to Indemnitee
all amounts for which Indemnitee shall be entitled to indemnification pursuant to this Agreement or otherwise, and (v) all unexpended
funds in the trust shall revert to the Corporation upon a final determination by the Independent Counsel or a court of competent
jurisdiction, as the case may be, that Indemnitee has been fully indemnified under the terms of this Agreement. The trustee shall
be chosen by Indemnitee. Nothing in this Paragraph 12 shall relieve the Corporation of any of its obligations under this Agreement.
All income earned on the assets held in the trust shall be reported as income by the Corporation for federal, state, local, and
foreign tax purposes. The Corporation shall pay all costs of establishing and maintaining the trust and shall indemnify the trustee
against any and all expenses (including attorneys’ fees), claims, liabilities, loss, and damages arising out of or relating
to this Agreement or the establishment and maintenance of the trust.

 

13.
Subrogation. In the event of any payment under this Agreement, the Corporation shall be subrogated to the extent of such
payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and take all action necessary to
secure such rights, including execution of such documents as are necessary to enable the Corporation to bring suit to enforce
such rights.

 

14.
Term of Agreement. This Agreement shall continue until and terminate upon the later of (a) six years after the date that
Indemnitee shall have ceased to serve as a director or officer of the Corporation or, at the request of the Corporation, as a
director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise; (b) the expiration
of all applicable statute of limitations periods for any claim which may be brought against Indemnitee in a Proceeding as a result
of his Corporate Status; or (c) the final termination of all Proceedings pending on the date set forth in clauses (a) or (b) in
respect of which Indemnitee is granted rights of indemnification or advancement of Expenses hereunder and of any proceeding commenced
by Indemnitee pursuant to Paragraph 10 of this Agreement relating thereto.

 

15.
Indemnification Hereunder Not Exclusive. The indemnification and advancement of Expenses provided by this Agreement shall
not be deemed exclusive of any other rights to which Indemnitee may be entitled under the Articles of Incorporation, the By-Laws,
any agreement, any vote of stockholders or disinterested directors, the applicable law of the State of D, and any other law (common
or statutory) or otherwise, both as to action in Indemnitee’s official corporate capacity and as to action in another capacity
while holding office for the Corporation. Nothing contained in this Agreement shall be deemed to prohibit the Corporation from
purchasing and maintaining insurance, at its expense, to protect itself or the Indemnitee against any expense, liability or loss
incurred by it or Indemnitee in any such capacity, or arising out of Indemnitee’s status as such, whether or not Indemnitee
would be indemnified against such expense, liability or loss under this Agreement; provided that the Corporation shall not be
liable under this Agreement to make any payment of amounts otherwise indemnifiable hereunder if and to the extent that Indemnitee
has otherwise actually received such payment under any insurance policy, contract, agreement or otherwise, including as provided
in Paragraph 5 hereof.

 

16.
No Special Rights. Nothing herein shall confer upon Indemnitee any right to continue to serve as a director or officer
of the Corporation for any period of time or, except as expressly provided herein, at any particular rate of compensation.

 

    	 	 	 

     

    

 

17.
Savings Clause. If this Agreement or any portion thereof shall be invalidated on any ground by any court of competent jurisdiction,
then the Corporation shall nevertheless indemnify Indemnitee as to Expenses, judgments, fines, penalties and amounts paid in settlement
with respect to any Proceeding to the full extent permitted by any applicable portion of this Agreement that shall not have been
invalidated and to the fullest extent permitted by applicable law.

 

18.
Counterparts; Signatures. This Agreement may be executed in two counterparts, both of which together shall constitute the
original instrument. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission
shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

 

19.
Successors and Assigns. This Agreement shall be binding upon the Corporation and its successors and assigns and shall inure
to the benefit of the estate, heirs, executors, administrators and personal representatives of Indemnitee.

 

20.
Headings. The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed to
constitute part of this Agreement or to affect the construction thereof.

 

21.
Modification and Waiver. This Agreement may be amended from time to time to reflect changes in applicable law or for other
reasons. No supplement, modification or amendment of this Agreement shall be binding unless executed in writing by both of the
parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other
provision hereof nor shall any such waiver constitute a continuing waiver.

 

22.
Notices. All notices, requests, demands and other communications hereunder shall be in writing and shall be deemed to have
been given (i) when delivered by hand or (ii) if mailed by certified or registered mail with postage prepaid, on the third day
after the date on which it is so mailed:

 

		(a)	If
                                         to the Indemnitee, to:	 
	 	 	 	 
	 	 	 	 
	 	 	 	 

 

		(b)	If
                                         to the Corporation, to:

 

TechCare
Corp.

1140
Avenue of the Americas

New
York, NY 10036

Attention:
Chief Executive Officer

 

or
to such other address as may have been furnished to Indemnitee by the Corporation or to the Corporation by Indemnitee, as the
case may be.

 

    	 	 	 

     

    

 

23.
Applicable Law. This Agreement is governed by and is to be construed in accordance with the laws of the State of Delaware
without giving effect to any provisions thereof relating to conflict of laws.

 

24.
Enforcement. The Corporation expressly confirms and agrees that it has entered into this Agreement in order to induce Indemnitee
to continue to serve as director and/or officer of the Corporation and acknowledges that Indemnitee is relying upon this Agreement
in continuing in such capacity.

 

[remainder
of page intentionally left blank]

 

    	 	 	 

     

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the day and year first above written.

 

	TECHCARE
    CORP.	 	INDEMNITEE:
    
	 	 	 	 
	By:	                                      	 	                                           
	Name: 	 	 	 
	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}]]